SIGHT — Gensight Biologics SA Share News
0.000.00%
Last trade - 00:00- €17.21m
- €28.38m
- €0.00m
France's GenSight Biologics H1 net loss widens on higher R&D expenses
Brief: GenSight Biologics H1 Net Income EUR -10.3 Million
France's GenSight Biologics 2025 net loss narrows on reduced R&D spending
Brief: GenSight Biologics FY EPS EUR -0.08
Brief: Gensight Biologics Announces The Results Of Its Extraordinary General Meeting Of January 28, 2026
Brief: Gensight Biologics Announces Regulatory Authorization For Early Access Treatment With Gs010/Lumevoq In Israel
Brief: Gensight Biologics's GS010/Lumevoq® Phase II Study To Start In Jan 2026
Brief: GenSight Biologics H1 EPS EUR -0.05
Brief: GenSight Biologics Announces An Additional Financing
Brief: Gensight Biologics Reaches Deal With ANSM For Opening Of Lumevoq Early Access Program In France
Brief: GenSight Biologics Announces Approval Of All Resolutions Supported By The Board Of Directors At The Combined General Meeting Of May 13, 2025
Brief: Gensight Biologics Announces Five-Year Efficacy And Safety Results For Lumevoq® Gene Therapy
Brief: Gensight Biologics SA Says LUMEVOQ Injections Expected In January 2025
Brief: Gensight Biologics Says Co Renegotiates Financial Obligations; Advancing On Discussions With Potential Partners On Strategic Opportunities
Brief: Gensight Biologics In Discussions To Secure Financing From End of April to Q3 2024
Brief: Gensight Biologics Reports FY Net Loss Up At -26.2 Million euros
Brief: Gensight Biologics Updates On Data From Lumevoq Gene Therapy Programs
Brief: Gensight Biologics Announces Completion Of EUR 5 Mln Capital Increase
Brief: Gensight Biologics Says Will Require Approx. EUR 14 Million To Finance Its Activities Until July 2024